Skip to main content
PLOS One logoLink to PLOS One
. 2024 Jul 25;19(7):e0304626. doi: 10.1371/journal.pone.0304626

Shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): Protocol for a realist review

Ita Fitzgerald 1,2,*, Laura J Sahm 2,3, Jo Howe 4, Ian Maidment 4, Emma Wallace 5, Erin K Crowley 2
Editor: Eleni Petkari6
PMCID: PMC11271866  PMID: 39052681

Abstract

Background

Shared decision-making (SDM) has yet to be successfully adopted into routine use in psychiatric settings amongst people living with severe mental illnesses. Suboptimal rates of SDM are particularly prominent amongst patients with psychotic illnesses during antipsychotic treatment choices. Many interventions have been assessed for their efficacy in improving SDM within this context, although results have been variable and inconsistent.

Aims

To generate an in-depth understanding of how, why, for whom, and to what extent interventions facilitating the application of SDM during antipsychotic treatment choices work and the impact of contextual factors on intervention effectiveness.

Methods

This review will use realist review methodology to provide a causal understanding of how and why interventions work when implementing SDM during antipsychotic treatment choices. The cohort of interest will be those experiencing psychosis where ongoing treatment with an antipsychotic is clinically indicated. The review will take place over five stages; (1) Locating existing theories, (2) Searching for evidence, (3) Selecting articles, (4) Extracting and organising data and (5) Synthesizing evidence and drawing conclusions. An understanding of how and why interventions work will be achieved by developing realist programme theories on intervention effectiveness through iterative literature reviews and engaging with various stakeholder groups, including patient, clinician and carer representatives.

Discussion

This is the first realist review aiming to identify generative mechanisms explaining how and why successful interventions aimed at improving SDM within the parameters outlined work and in which contexts desired outcomes are most likely to be achieved. Review findings will include suggestions for clinicians, policy and decision-makers about the most promising interventions to pursue and their ideal attributes.

Introduction

Shared Decision-Making (SDM) is advocated as an ideal model of treatment decision-making in mental health and is a key component of person-centred care [1, 2]. SDM is a concept of non-paternalistic communication between patients and clinicians, and is most commonly defined as a process in which clinicians and patients work together to select treatments based on clinical evidence and the patient’s informed preferences [2]. International mental health policies have increasingly advocated partnership models of mental health care, including the application of SDM in treatment decisions [13]. In the treatment of severe mental illnesses, the application of SDM may be particularly complicated [4]. Complexity in the application of the ideas and ideals of SDM may be particularly prominent in the treatment of schizophrenia and other enduring psychotic illnesses. During acute psychosis, a patient’s decision-making capacity may be impaired to a significant degree, resulting in specific challenges for clinicians in the implementation of SDM in initial antipsychotic treatment decisions. Furthermore, the possibility of involuntary admission for treatment can create extreme forms of ‘power asymmetry’ and the importance of long-term antipsychotic adherence requires special attention to patient satisfaction with treatment [4].

The principles of SDM may, however, be particularly well-suited to the selection of antipsychotic drug treatment, an integral component of psychosis management [5]. Antipsychotic choice is considered largely a preference-sensitive decision [5, 6], where differences between antipsychotics primarily centre on differences in side effects rather than efficacy [7]. In such cases, choice of antipsychotic treatment is significantly influenced by the individual’s preferences for likely side effects [6]. Such preference-sensitive decisions have been identified as an ideal target for SDM [6, 8]. Research has shown that the practice of SDM is highly acceptable amongst patients with enduring psychotic illnesses and psychiatrists [911], although differences in attitudes towards and subsequent participation in SDM have been identified in the case of the latter [12]. However, the practice of SDM has yet to be successfully adopted for routine use in psychiatric settings amongst patients with severe mental illnesses [13]. Suboptimal rates of SDM adoption are particularly prominent during antipsychotic treatment decisions amongst patients with psychotic illnesses [12, 14, 15]. Suggested reasons for low adoption rates of SDM in these contexts include clinicians’ belief that patients with psychosis have low decisional capacity and cognitive (poor attention, deficits in working memory and verbal fluency) and motivational deficits [11, 16].

Studies assessing varying interventions aimed at improving the application of SDM in choice of antipsychotic treatment during psychosis have been undertaken [2]. Interventions have largely been modelled on the application of SDM models in somatic medicine, with additional design features to account for implementation within psychiatric settings [4]. Interventions assessed typically include a combination of decision aids [17, 18], educational interventions for patients and/or clinicians [14], and digital support tools [1921]. To date, the effect size of studied interventions has proven variable and inconsistent [2, 22] and positive results are generally smaller than in somatic medicine [4, 22, 23]. Reasons for varying results, including an understanding of which elements of efficacious interventions are hypothesized to be responsible for results and how they produced their effects, are largely missing from the literature. An understanding of these mechanisms is important to support increased and standardised application of SDM in antipsychotic treatment decisions.

As highlighted, applying SDM in choice of antipsychotic treatment during psychosis is associated with significantly more complexity than in somatic medicine [13]. Interventions are also expected to be embedded within existing complex environments and within systems which have traditionally used paternalistic, clinician-led decision making [1, 24]. Refinements and adaptations of traditional SDM models, in general and for local contexts, are likely needed to improve effectiveness, including consideration of contextual factors relating to patients, clinicians, and the clinical encounter [14]. Although information exchange is an essential element in facilitating SDM [24], the neglect of wider structural and contextual factors in the design and implementation of SDM in choice of antipsychotic treatment may be one reason for varying results and suboptimal implementation of SDM interventions [1, 15]. Thus, uncertainty exists about which intervention types to preferentially implement, characteristics of interventions to improve the likelihood of achieving desirable outcomes and the impact of different contexts on intervention effectiveness.

Any review that seeks to understand SDM interventions, including how they produce their effects, needs to look beyond the intervention and seek to make sense of the wider context. This need to account for context and to address questions of how and why interventions work provides the rationale for using realist review methods in this evidence synthesis [25]. Realist reviews aim to move from empirical observation to developing theoretical causal explanations to understand what it is about interventions that generate change (i.e., the mechanisms), and under what circumstances the mechanisms are triggered (i.e., the contexts), which result in changes in behaviour of the participants of the intervention (i.e., the outcome) [26]. These three elements i.e., context, mechanism, and outcome configurations (CMOC), are presented together as a programme theory which attempts to describe what needs to happen for the intervention to work. A realist approach to evidence synthesis offers distinctive strengths in addressing questions of what works, for whom, under what circumstances and how when attempting to develop complex interventions where generated outcomes are likely variable and context-dependent [27].

Aims and objectives

This realist review aims to understand how interventions designed to improve SDM during antipsychotic treatment choices work and the impact of contextual factors on intervention success.

Review objectives include:

  1. Review the literature to identify what interventions have been studied in improving SDM in antipsychotic treatment choices (e.g., choice of initial antipsychotic treatment, change of treatment, or continuation of initial treatment) amongst patients with a psychotic illness where SDM in the clinical context is preferred.

  2. Apply a realist logic of analysis to the literature to understand how and why interventions have or have not achieved their desired outcomes.

  3. Engage with key stakeholders including prescribers and clinicians/practitioners who support prescribing (pharmacists, nurses, social workers), patients, carers and family members to identify problems in engaging in SDM within the context outlined.

  4. Synthesize the findings into a realist programme theory outlining context-mechanism-outcome configurations to explain intervention effectiveness.

  5. Provide recommendations on co-creating, tailoring, and implementing interventions to improve SDM during antipsychotic treatment choices in patients with a psychotic illness.

Methods

Realist And Meta-narrative Evidence Synthesis: Evolving Standards (RAMESES) guidance will be followed throughout the review process [28]. While this review will be conducted and reported according to RAMESES standards for realist syntheses, the research team have also populated the PRISMA-P checklist to provide additional oversight in the methology of this review (see S1 Checklist). The review protocol has been registered with PROSPERO (CRD42023443783) on the 13/10/23 prior to review commencement. The review will follow five iterative stages based on Pawson’s realist methodology, although the process of moving through the steps will proceed in a non-linear fashion [26, 29, 30] Fig 1 provides an overview of the five steps to be applied in this review [31, 32].

Fig 1. Project flow diagram.

Fig 1

* Movement between steps if necessary to further refine programme theory. Adapted from review by Duddy et al. [31].

Step 1: Locate existing theories

The rationale of this step is to identify a range of possible theories that explain how interventions aimed at improving SDM in decisions of antipsychotic treatment are supposed to work (and for whom), when they do work (or do not) and why they are not being used [2527]. To locate these theories, we will (1) perform exploratory literature searches and (2) consult with members of the project team and stakeholder groups and draw on their experiential, professional and content knowledge. The project team represents multi- and inter-disciplinary professionals within psychiatry, academia and those with experience in education and clinical training. This step is more exploratory and aimed at quickly identifying the range of possible explanatory theories that may be relevant to the review question [25]. For this step, PubMed/MEDLINE, PsycINFO and Open Grey will be used.

Following these searches and discussions with stakeholder groups, iterative discussions within the project team will be held to interpret and synthesize the different theories into an initial, coherent programme theory. Meetings of the project team and stakeholder groups will be held online via Microsoft Teams. Discussion may also be held via telephone calls and e-mail exchange. Detailed notes of all meetings will be kept to support programme theory development and refinement and to serve as a clear audit trail. From these processes, an initial programme theory for subsequent testing in the review will be developed.

Stakeholder group—Clinicians/practitioners

The clinician and practitioner stakeholder group will include representation from consultant psychiatrists, non-consultant psychiatric doctors, psychiatric nursing, psychiatric pharmacy,general practitioners and community pharmacy. We aim to identify 12–20 members will be identified through places of work, partnership organisations and through contacts of the project team. We will extend the membership as needed for testing of the emerging programme theory.

Stakeholder group—Service users, informal and formal carer givers

Those with lived experience of psychosis and taking antipsychotic medications will be identified within via the Service User Advisory Network in St Patrick’s Mental Health Services (SPMHS), Dublin, Ireland. Carers will be identified via the Family Members, Carers and Supporters Advisory Network in SPMHS. Both are established patient and carer stakeholder groups which afford local researchers the opportunity to set up advisory or consultation groups specific to the research project. We will also contact local charitable or public engagement organisations to recruit a diverse stakeholder group, if required. We aim to recruit 8–12 people across both cohorts. To ensure equal representation of the voice of both clinical expertise and expertise by experience, meetings of the clinician and lived experience stakeholder groups will meet separately. Similarities and differences in feedback from both groups will be shared with the other, and reasons for differences explored.

Step 2—Searching for evidence

The purpose of this step is to find a relevant body of literature with which to further develop and refine the emerging programme theory formed in Step 1. Further programme theory refinement will use data identified via formal literature searches [2527]. Once the initial programme theory has been developed as per Step 1, we will then be able develop the search strategy in full, as in other reviews [25, 26, 33, 34, 35]. For all searches, searching will be designed, piloted and conducted by one researcher (IF) with support from the project team and an academic librarian. We plan to conduct iterative searches of the literature with different search term concepts and permutations to capture the most relevant data relating to the emerging programme theory and any additional research that may add to the conceptual and contextual richness of the studies [27, 35]. Modification of the search strategy including terms searched, inclusion and exclusion criteria and databases used may be undertaken depending on the emerging programme theory. The proposed initial sampling frame to be used as the basis for the comprehensive literature search is outlined in Table 1.

Table 1. Overview of inclusion and exclusion criteria.

Population Include:
• Adult participants (aged 18–65) experiencing an episode of psychosis in the context of a psychotic illness where extended antipsychotic treatment is clinically indicated.
Exclude:
• Participants with treatment-resistant schizophrenia due to existence of clozapine as a preferred treatment choice amongst this cohort.
Participants experiencing substance/medication-induced psychosis or psychosis in the context of a general medical condition.
Intervention Any intervention designed to facilitate SDM between clinicians and patients in decisions of antipsychotic treatment as part of psychosis management.
Given the role of collaborative goal setting and action planning in SDM in long-term conditions [36], alongside internalised stigma that can exist amongst those with mental illnesses [37], we will also include interventions that consist of SDM educational or training programmes for either patients and/or clinicians.
Comparator Not applicable
Outcome Outcomes of SDM processes have been assessed in a variety of different ways, relating to both process and outcome measurements [2]. This review will include outcomes relating to evidence of SDM application, including improved level of patient and clinician involvement in the decision-making process. Patient perceived involvement in decision-making can be assessed via many ways [2], for example the Shared-Decision Making Questionnaire (SDM-Q-9), the CollaboRATE scale or the Perceived Involvement in Care Scale (PICS) [38].
Other eligible outcomes relating to improving the likelihood of patient engagement in SDM specific to mental health settings [39], including patient-reported improved knowledge, empowerment, self-determination and satisfaction with treatment, will also be considered.
Other unanticipated outcomes may also be included in the review. For example, measures of patient satisfaction with care or quality of life measures may be relevant.
If SDM outcome assessment includes clinical outcomes, for example, improved adherence or reduced hospitalisation, these studies will also be included.
Outcomes also relating to physicians perceived involvement in SDM practices will be included, for example using the physician version of the SDM-Q-9-Doc [40].
Timing Use of interventions to inform choice of antipsychotic treatment (including initial treatment, change of treatment or continuation of treatment) as part of acute psychosis management.
Setting Inpatient and outpatient settings, including community mental health teams and primary care settings to account for differing designs of mental health services internationally in the management of psychosis.
Forensic settings will be excluded.
The need for different programme theories for different settings will be considered by the research team.

Based on discussion with an academic librarian, we anticipate that we may need to search the following bibliographic databases: PubMed/MEDLINE, Embase, PsycINFO, CINAHL, the Cochrane library, Web of Science, Scopus and Sociological Abstracts. Additional searches for grey literature may be undertaken if required for programme theory refinement using the bibliographic databases Open Grey, ProQuest Dissertations, ResearchGate, Google Scholar, and Theses and DART-Europe-E-theses Portal. A combination of free-text and indexing search terms will be selected and adapted for the database being searched. There will be no restrictions on study type. Given the range of conceptual definitions of ‘shared decision-making’ and associated terminology, and the majority of research in this area being conducted amongst participants with schizophrenia [6, 18, 41], we will structure the search strategy according to schizophrenia and psychotic illness search terms and shared decision-making terms, with the later derived from work conducted by Makoul et al. [42] Alerts for new articles which fit the search terms applied will be set to facilitate timely addition of new relevant articles during programme theory development. Only English language studies will be included due to study resources. A date restriction of 1990 to present will be applied. This reflects the timeline over which person-centred and recovery-focussed care in mental health became the dominant paradigms and associated application of SDM became advocated as the ideal model of treatment decision-making [1, 2].

Database searching will be supplemented by additional search methods. We will conduct backwards and forwards citation searching using Web of Science. We will also use ‘cluster searching’ techniques [33]. This includes ‘sibling’ (i.e. directly linked outputs from a single study) and ‘kinship’ (i.e. associated papers with a shared contextual or conceptual pedigree) papers [33, 43]. We will liaise with members of our stakeholder groups and additional links amongst the project team to recommend any potentially relevant documents. Searching will continue until sufficient data is found to conclude that the refined programme theory or theories are sufficiently coherent and plausible [27]. If the volume of the literature retrieved proves excessive, a variety of appropriate sampling strategies will be used (e.g. theoretical sampling, maximum variation sampling) to ensure that we have sufficiently focussed but relevant data for programme theory development [27, 33].

The results of all searches will be exported to Covidence systematic review software. Covidence is a web-based collaboration software platform that streamlines the production of systematic and other literature reviews (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia; see http://www.covidence.org). Following duplicate removal, screening of titles, abstracts and keywords of potentially relevant articles will be undertaken by one member of the research team (IF). A 10% random subsample of all studies will be reviewed independently by another researcher (LS/EC/IM/JH/EW) against the inclusion criteria for any systematic errors. Inclusion and exclusion criteria will be finalised by the project team following Step 1. Disagreements will be resolved by discussion and recourse to an independent member of the project team until consensus is achieved [26, 32].

Step 3: Selecting articles

Screening of full-text articles identified for potential inclusion will be undertaken by one researcher (IF). Covidence software will also be used for this step. The selection of articles for final inclusion will primarily focus on relevance (whether data could contribute to some aspect of the testing and advancement of the programme theory) and rigour (whether the methods used to generate the relevant data are credible and trustworthy to warrant making changes to the programme theory) [27]. As in other studies and in line with best practice within realist review methodology [2527, 32, 33], whilst we will consider the quality of each individual data source, we will conceptualise assessments of quality at a more global level. Judgements about quality will be made at the levels of data, argument, and programme theory. To operationalise such assessments, we plan to do the following [44]:

  1. Find more than one source of data relevant to each aspect of the developing programme theory.

  2. In cases of opinions etc; we will treat such data with scepticism initially until further supporting evidence is identified.

  3. During building of programme theory, results will be presented initially partially, then in full, to stakeholder groups to aid in interpretation and to support development of a rigorous final programme theory.

  4. We will seek to find to relevant substantive theory to support arguments made within the programme theory.

  5. In cases of inadequate data, or use primarily of data judged to be of poor quality to support any aspect of the programme theory, we will cautiously report such statements with appropriate qualifiers regarding the quality of data.

  6. We will provide access to supporting data taken from each listed data source at the point of publication to allow for critical appraisal by peers.

One researcher (IF) will read all included data sources that appear to contain data relevant to the realist analysis i.e., could inform some aspect of the programme theory. Reasons for exclusion of each study will be noted, for example if records are classified by the research team as having low relevance to the programme theory. For those articles deemed to meet the inclusion criteria, IF will retrieve the full text and classify documents into high and low relevance, depending on their relevance to the programme theory, and based on established methods previously employed [45, 46]. Briefly, full-text documents will be assigned a star rating of one to five, based on a global judgement of each document’s relevance and rigour.Documents assigned a one- or two-star rating will be deemed irrelevant and not included in the review. Three-star documents will be deemed irrelevant for programme theory development but potentially useful for background material. Four-star documents will be classified as relevant for programme theory refinement. Five-star documents will be deemed the most conceptually rich or contextually thick and so, most relevant to CMOC development and programme theory refinement.

All 1–3-star documents will be reviewed again before finalisation of the programme theory (ies) to confirm appropriate classification [35, 43, 44]. A random subsample of the 10% of final documents for inclusion based on their assigned relevance and rigour judgement will be selected and assessed independently by another member of the research team (LS/EC/IM/JH/EW) to identify systematic errors [26, 32]. The remaining 90% of decisions will be made by IF, although a number of these may require further discussion/joint reading between the wider project team due to issues of uncertainty regarding relevance and/or rigour. Discussions will continue until consensus is reached.

Step 4: Extracting and organising data

Data extraction and organisation will be undertaken by one researcher (IF) using Microsoft Excel. Study characteristics to be extracted include:

  • Study details (publication year, location of study)

  • Study objectives

  • Intervention description

  • Study design and quality markers (rigour, relevance)

  • Study methods

  • Sample characteristics (age, gender, ethnicity)

  • Contextual factors (mechanisms) before the intervention was introduced

  • Outcomes and how they were measured

The full texts of all included papers will be uploaded to NVivo qualitative data analysis software. Documents will be examined for data on how SDM interventions work by applying a realist logic of analysis to relevant sections of the text. The synthesis of evidence will begin with conceptual coding. Sections of text will be coded in broad conceptual categories (‘conceptual buckets’) for example, developing therapeutic alliance, adequate information sources, beginning with the richest sources i.e. articles with the most potential to inform the programme theory. As the review progresses, these conceptual codes will be analysed to develop context-mechanism-outcome configurations (CMOC) [45]. Allocation of codes will be both inductive and deductive. Retroductive coding will also be applied i.e. where codes are created based on an interpretation of data to infer potential hidden causal mechanisms for outcomes [33, 45, 47]. Each new element of coded data will be used to refine the programme theory, as appropriate. As the theory is refined, included studies will be re-scrutinised for data relevant to the revised theory that may have been missed initially [33, 47]. This step will initially be completed by one researcher (IF) with support from other members of the team experienced in realist methodology (JH/IM). The project team will examine the viability of different CMOCs, experiment with varying formulations and work towards building the narrative of the evidence synthesis [32]. The developing programme theory will be confirmed with the rest of the project team iteratively and at defined stages. In the case of data extraction and coding of papers, a 10% random subsample of papers will be reviewed independently by other members of the research team (EW/LS/IM/JH/EC) as part of quality control measures. Any disagreements will be resolved via discussion until consensus is achieved.

Step 5: Synthesising the evidence and drawing conclusions

To develop the final programme theory, we will move iteratively between the analysis of certain sections of included papers, stakeholder group interpretation and further iterative searching for data in the included studies to refine the programme theory and its subsections. The purpose of this step is to understand how mechanisms behave under the different contexts described within the review documents [27, 46]. We will move from data to theory to refine explanations about why certain interventions are effective (or not). This will include inferences about which mechanisms may be triggered in specific circumstances and contexts, as these are likely to be hidden and not explicitly or adequately referred to in the literature [28]. Relationships between context, mechanism and outcomes will be sought across articles included. In keeping with the application of a realist logic of analysis, a series of questions will be used to support the analysis and synthesis of data including [27, 33, 47]:

  • Interpretation of meaning: if relevant and trustworthy, do the contents of the included document provide data that may be interpreted as functioning as context, mechanism or outcome?

  • Interpretation and judgements about CMOCs: For example, what is the CMOC (partial or complete) for the data that has been interpreted as functioning as context, mechanism, or outcome? Are there further data to inform this particular CMOC contained within this source or other sources?

  • Interpretations and judgements about programme theory: For example, how does this (full or partial) CMOC relate to the programme theory under development? Within the same document, are there data which informs how the CMOC relates to the programme theory?

When working through these questions, where appropriate, we will apply the following forms of reasoning to make sense of the data: juxtaposition of the data, reconciliation of the data, adjudication of the data and consolidation of the data [32, 33]. All members of the project team will be involved in generation of the final programme theory/theories.

Ethics

Primary data will not be collected and therefore, ethical approval is not required for this review.

Discussion

Novelty of the review

This review will be the first realist review of the literature examining interventions aimed at improving SDM application during antipsychotic treatment choices amongst those with an enduring psychotic illness. The review will blend empirical research with the views, experience, and expertise of people with lived experience of psychosis, professionals and practitioners in this field, academics and topic experts. Systematic review findings suggest that several interventions are helpful in promoting the application of SDM within this context [2]. The literature has, however, focused on the effectiveness and impact of interventions, without considering underlying processes and contextual influences. There is a need for further evidence on how interventions work, for whom and under what circumstances to understand what can be done to maximise their chances of success. The review aims to identify those generative mechanisms underlying effective interventions and in which contexts are the desired outcomes most likely to be achieved. The findings of the review will enable us to provide suggestions for clinicians, policy and decision-makers about the most promising interventions to pursue and their ideal attributes, and what refinements are needed for local tailoring and implementation.

Impact and dissemination

Review results will be used to inform future policy, research and practice in in this area. The research team will share findings through their networks and promote change beyond the end of the project. The findings of this realist review will also be made public through a peer-reviewed open access publication. Findings will be disseminated and shared through knowledge exchange with stakeholders and policymakers at a national and international level via conferences and personal communication. Key stakeholders within the project and wider team (including stakeholder groups) will be consulted to disseminate findings through their local and national networks. To increase the accessibility of the review findings, user-friendly summaries will be produced and tailored suitable for healthcare professionals, service users and their families. Use of social media platforms will be considered to increase engagement from the wider population.

Supporting information

S1 Checklist. PRISMA-P 2015 checklist.

(DOCX)

pone.0304626.s001.docx (34.6KB, docx)

Acknowledgments

We would like to thank academic librarian Virginia Conrick for her assistance in the preparation of search strategy for this review.

Data Availability

No results are reported - this is a protocol paper. Data availability statement not required.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Slade M. Implementing shared decision making in routine mental health care. World Psychiatry 2017;16(2): 146–53. doi: 10.1002/wps.20412 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Aoki Y, Yaju Y, Utsumi T, Sanyaolu L, Storm M, Takaesu Y, et al. Shared decision‐making interventions for people with mental health conditions. Cochrane Database Syst Rev 2022; 11. Available from: doi: 10.1002/14651858.CD007297.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.NICE. Overview | Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services. 2011 [cited August 2023]. Available from: https://www.nice.org.uk/guidance/cg136
  • 4.Beitinger R, Kissling W, Hamann J. Trends and perspectives of shared decision-making in schizophrenia and related disorders. Curr Opin Psychiatry 2014;27(3): 222–229. doi: 10.1097/YCO.0000000000000057 [DOI] [PubMed] [Google Scholar]
  • 5.NICE. Recommendations | Psychosis and schizophrenia in adults: prevention and management | Guidance. 2014 [cited March 2023]. Available from: https://www.nice.org.uk/guidance/cg178/chapter/Recommendations
  • 6.Müller K, Schuster F, Rodolico A, Siafis S, Leucht S, Hamann J. How should patient decision aids for schizophrenia treatment be designed?—A scoping review. Schizophr Res 2023;255: 261–73. doi: 10.1016/j.schres.2023.03.025 [DOI] [PubMed] [Google Scholar]
  • 7.Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet 2019;14(394): 939–951. doi: 10.1016/S0140-6736(19)31135-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Morant N, Kaminskiy E, Ramon S. Shared decision making for psychiatric medication management: beyond the micro-social. Health Expect 2016; 19(5): 1002–14. doi: 10.1111/hex.12392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry 2005;162(12): 2382–4. doi: 10.1176/appi.ajp.162.12.2382 [DOI] [PubMed] [Google Scholar]
  • 10.Seale C, Chaplin R, Lelliott P, Quirk A. Sharing decisions in consultations involving anti-psychotic medication: a qualitative study of psychiatrists’ experiences. Soc Sci Med 2006;62(11): 2861–73. doi: 10.1016/j.socscimed.2005.11.002 [DOI] [PubMed] [Google Scholar]
  • 11.Hamann J, Mendel R, Cohen R, Heres S, Ziegler M, Bühner M, et al. Psychiatrists’ Use of Shared Decision Making in the Treatment of Schizophrenia: Patient Characteristics and Decision Topics. Psychiatr Serv 2009;60(8): 1107–12. doi: 10.1176/ps.2009.60.8.1107 [DOI] [PubMed] [Google Scholar]
  • 12.Haugom EW, Stensrud B, Beston G, Ruud T, Landheim AS. Experiences of shared decision making among patients with psychotic disorders in Norway: a qualitative study. BMC Psychiatry 2022;22(1):192. Available from: doi: 10.1186/s12888-022-03849-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zisman-Ilani Y, Roth RM, Mistler LA. Time to Support Extensive Implementation of Shared Decision Making in Psychiatry. JAMA Psychiatry 2021;78(11):1183–4. doi: 10.1001/jamapsychiatry.2021.2247 [DOI] [PubMed] [Google Scholar]
  • 14.Hamann J, Holzhüter F, Blakaj S, Becher S, Haller B, Landgrebe M, et al. Implementing shared decision-making on acute psychiatric wards: a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS). Epidemiol Psychiatr Sci 2020; 16(29):e137. Available from: doi: 10.1017/S2045796020000505 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Grunwald LM, Thompson J. Re-starting the conversation: improving shared decision making in antipsychotic prescribing. Psychosis 2021;13(4): 373–377. [Google Scholar]
  • 16.Larkin A, Hutton P. Systematic review and meta-analysis of factors that help or hinder treatment decision-making capacity in psychosis. Br J Psychiatry 2017;211(4): 205–15. doi: 10.1192/bjp.bp.116.193458 [DOI] [PubMed] [Google Scholar]
  • 17.Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, et al. Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand 2006;114(4):265–73. doi: 10.1111/j.1600-0447.2006.00798.x [DOI] [PubMed] [Google Scholar]
  • 18.Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry 2007;68(7):992–7. doi: 10.4088/jcp.v68n0703 [DOI] [PubMed] [Google Scholar]
  • 19.Vitger T, Hjorthøj C, Austin SF, Petersen L, Tønder ES, Nordentoft M, et al. A Smartphone App to Promote Patient Activation and Support Shared Decision-making in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings (Momentum Trial): Randomized Controlled Assessor-Blinded Trial. J Med Internet Res 2022;26;24(10):e40292. Available from: doi: 10.2196/40292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mueser KT, Penn DL, Addington J, Brunette MF, Gingerich S, Glynn SM, et al. The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. Psychiatr Serv 2015;66(7): 680–90. doi: 10.1176/appi.ps.201400413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Tasma M, Roebroek LO, Liemburg EJ, Knegtering H, Delespaul PA, Boonstra A, et al. The development and evaluation of a computerized decision aid for the treatment of psychotic disorders. BMC Psychiatry 2018;18(1): Available from: 10.1186/s12888-018-1750-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chmielowska M, Zisman-Ilani Y, Saunders R, Pilling S. Trends, challenges, and priorities for shared decision making in mental health: The first umbrella review. Int J Soc Psychiatry 2023;69(4): 823–840 doi: 10.1177/00207640221140291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Keij SM, Boer JE de, Stiggelbout AM, Bruin WB de, Peters E, Moaddine S, et al. How are patient-related characteristics associated with shared decision-making about treatment? A scoping review of quantitative studies. BMJ Open 2022;12(5):e057293. Available from: doi: 10.1136/bmjopen-2021-057293 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997;44(5):681–92. doi: 10.1016/s0277-9536(96)00221-3 [DOI] [PubMed] [Google Scholar]
  • 25.Wong G, Brennan N, Mattick K, Pearson M, Briscoe S, Papoutsi C. Interventions to improve antimicrobial prescribing of doctors in training: the IMPACT (IMProving Antimicrobial presCribing of doctors in Training) realist review. BMJ Open 2015;5(10):e009059. Available from: doi: 10.1136/bmjopen-2015-009059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Haines-Delmont A, Tsang A, Szifris K, Craig E, Chapman M, Baker J, et al. Approaches used to prevent and reduce the use of restrictive practices on adults with learning disabilities: Protocol for a realist review. PLoS One 2022;17(9):e0270028. Available from: doi: 10.1371/journal.pone.0270028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (Realist And Meta-narrative Evidence Syntheses–Evolving Standards) project [Internet]. Southampton (UK): NIHR Journals Library; 2014. [cited 2023 Mar 31]. (Health Services and Delivery Research). Available from: http://www.ncbi.nlm.nih.gov/books/NBK260013/ [PubMed] [Google Scholar]
  • 28.Duddy C, Wong G. Grand rounds in methodology: when are realist reviews useful, and what does a ‘good’ realist review look like? BMJ Qual Saf 2023;32(3):173–80. doi: 10.1136/bmjqs-2022-015236 [DOI] [PubMed] [Google Scholar]
  • 29.Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol—realist and meta-narrative evidence synthesis: Evolving Standards (RAMESES). BMC Med Res Methodol 2011;11. Available from: 10.1186/1471-2288-11-115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wong G. REALIST REVIEWS IN HEALTH POLICY AND SYSTEMS RESEARCH [Internet]. Evidence Synthesis for Health Policy and Systems: A Methods Guide. World Health Organization; 2018. [cited 2023 Feb 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK569577/ [Google Scholar]
  • 31.Saul JE, Willis CD, Bitz J, Best A. A time-responsive tool for informing policy making: rapid realist review. Implement Sci 2013;8(1):103. doi: 10.1186/1748-5908-8-103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Papoutsi C, Mattick K, Pearson M, Brennan N, Briscoe S, Wong G. Social and professional influences on antimicrobial prescribing for doctors-in-training: a realist review. J Antimicrob Chemother 2017;72(9):2418–30. doi: 10.1093/jac/dkx194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Maidment I, Wong G, Duddy C, Upthegrove R, Oduola S, Allen K, et al. Medication optimisation in severe mental illness (MEDIATE): protocol for a realist review. BMJ Open 2022;12(1):e058524. Available from: doi: 10.1136/bmjopen-2021-058524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Maidment ID, Wong G, Duddy C, Upthegrove R, Oduola S, Robotham D, et al. REalist Synthesis Of non-pharmacologicaL interVEntions for antipsychotic-induced weight gain (RESOLVE) in people living with severe mental illness (SMI). Syst Rev 2022;11(1):42. Available from: doi: 10.1186/s13643-022-01912-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Duddy C, Wong G, Gadsby EW, Krska J, Hibberd V. NHS Health Check programme: a protocol for a realist review. BMJ Open 2021;11(4):e048937. Available at: doi: 10.1136/bmjopen-2021-048937 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care planning for adults with chronic or long‐term health conditions. Cochrane Database Syst Rev 2015; 2015(3):CD010523. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486144/ doi: 10.1002/14651858.CD010523.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Drapalski AL, Lucksted A, Perrin PB, Aakre JM, Brown CH, DeForge BR, et al. A Model of Internalized Stigma and Its Effects on People With Mental Illness. Psychiatr Serv 2013;64(3):264–9. doi: 10.1176/appi.ps.001322012 [DOI] [PubMed] [Google Scholar]
  • 38.Ubbink DT, van Asbeck EV, Aarts JWM, Stubenrouch FE, Geerts PAF, Atsma F, et al. Comparison of the CollaboRATE and SDM-Q-9 questionnaires to appreciate the patient-reported level of shared decision-making. Patient Educ Couns. 2022;105(7): 2475–9. doi: 10.1016/j.pec.2022.03.007 [DOI] [PubMed] [Google Scholar]
  • 39.Zisman-Ilani Y, Chmielowska M, Dixon LB, Ramon S. NICE shared decision making guidelines and mental health: challenges for research, practice and implementation. BJPsych Open 2021;7(5):e154. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444056/ doi: 10.1192/bjo.2021.987 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Scholl I, Kriston L, Dirmaier J, Buchholz A, Härter M. Development and psychometric properties of the Shared Decision Making Questionnaire-physician version (SDM-Q-Doc). Patient Educ Couns 2012;88(2):284–90. doi: 10.1016/j.pec.2012.03.005 [DOI] [PubMed] [Google Scholar]
  • 41.Siafis S, Bursch N, Müller K, Schmid L, Schuster F, Waibel J, et al. Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia. BMC Psychiatry 2022;22(1):406. doi: 10.1186/s12888-022-04036-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ Couns 2006;60(3): 301–12. doi: 10.1016/j.pec.2005.06.010 [DOI] [PubMed] [Google Scholar]
  • 43.Booth A, Harris J, Croot E, Springett J, Campbell F, Wilkins E. Towards a methodology for cluster searching to provide conceptual and contextual “richness” for systematic reviews of complex interventions: case study (CLUSTER). BMC Med Res Methodol 2013;13(1):118. Available from: doi: 10.1186/1471-2288-13-118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Wong Geoff. Data Gathering in Realist Reviews: Looking for needles in haystacks. Doing Realist Research. London: SAGE Publications; 2018. p. 131–146 [Google Scholar]
  • 45.Howe J, MacPhee M, Duddy C, Habib H, Wong G, Jacklin S, et al. A realist review of medication optimisation of community dwelling service users with serious mental illness. medRxiv [preprint] 2023. Available from: https://www.medrxiv.org/content/10.1101/2023.08.02.23293542v1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Dada S, Dalkin S, Gilmore B, Hunter R, Mukumbang FC. Applying and reporting relevance, richness and rigour in realist evidence appraisals: Advancing key concepts in realist reviews. Res Synth Methods 2023;14(3): 504–14. doi: 10.1002/jrsm.1630 [DOI] [PubMed] [Google Scholar]
  • 47.Price T, Brennan N, Cleland J, Prescott-Clements L, Wanner A, Withers L, et al. Remediating doctors’ performance to restore patient safety: a realist review protocol. BMJ Open 2018; 8(10):e025943. Available from: https://bmjopen.bmj.com/content/8/10/e025943 doi: 10.1136/bmjopen-2018-025943 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Eleni Petkari

5 Apr 2024

PONE-D-23-34877Shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): protocol for a realist reviewPLOS ONE

Dear Dr. Fitzgerald,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 19 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Eleni Petkari

Academic Editor

PLOS ONE

Journal requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We noticed you have some minor occurrence of overlapping text with the following previous publication, which needs to be addressed:

-https://doi.org/10.1371/journal.pone.0270028

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

3. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

********** 

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors,

I have reviewed your manuscript "Shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): protocol for a realist review." It is my pleasure to recommend its acceptance.

Your manuscript stands out for its adherence to the RAMESES project principles, contributing to its methodological strength. The choice of a realist review is particularly apt given the noted heterogeneity in outcomes of traditional review methods in this field. Additionally, your inclusive approach of involving various stakeholders, notably patients, is praiseworthy and enriches the study's depth and applicability.

Your work addresses a crucial aspect of mental health research and has the potential to significantly impact clinical practices and inform policy-making in the treatment of psychosis. I commend your efforts in enhancing patient-centered care through this research.

Congratulations on a well-executed study. I look forward to its publication and the impact it will have on the field.

Best regards,

Antonio Di Francesco

Reviewer #2: Thank you for the opportunity to review your work.

The authors present a protocol for a realist review study that aims to generate an in-depth understanding of interventions to facilitate the application of shared decision-making during the choice of antipsychotic drug treatment. The authors conclude that their review will be the first realist review that will identify generative mechanisms that explain how and why successful interventions aimed at improving shared decision-making in antipsychotic drug treatments and will identify which contexts desired outcomes of shared decision-making interventions would be most likely to be achieved.

I commend the authors on the work put forth to complete this protocol. This is an important topic that highlights an ongoing clinical issue of identifying the best approach to facilitating shared decision-making for antipsychotic treatment in psychotic illness. The protocol manuscript is overall clear, well-written, and reports an appropriate and rigorous methodologic approach. I provide the following suggestions for strengthening the manuscript.

1. The review protocol appears to be focused on shared decision-making on antipsychotic drug treatments in the setting of psychotic illness. However, this is not clear within the aims and/or methods of the abstract. Would the authors be able to clarify this detail in their manuscript?

2. The inclusion of multiple stakeholder groups including clinicians and service users as well as informal and formal caregivers is a strength of the study protocol and I commend the authors for using this comprehensive approach. When engaging with stakeholder groups that include service users and informal and formal caregivers, how will the authors ensure that perspectives of these stakeholder groups are prioritized and integrated among the larger stakeholder group of clinicians and practitioners?

3. The authors identify the patient population of interest to include adult participants aged 18-65 years. Would the authors be able to clarify the rationale for exclusion of those participants over the age of 65 years?

4. The authors report that during full-text screening that articles will be classified into high and low relevance based on previous established methods. It would be helpful to the reader to briefly explain how articles will be defined as having high or low relevance in the study.

5. How do the authors intend to evaluate rigor (i.e., trustworthiness) when completing qualitative data analysis during evidence synthesis?

I thank the authors for the opportunity to review this manuscript.

********** 

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Antonio Di Francesco

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Jul 25;19(7):e0304626. doi: 10.1371/journal.pone.0304626.r002

Author response to Decision Letter 0


3 May 2024

Dear Dr Petkari,

Many thanks to you and your reviewers for providing positive feedback regarding our manuscript and your constructive comments. We have responded to reviewer comments below in red. Sections of the manuscript which we have subsequently amended are contained here and have been highlighted within this response for ease of identification of amendments.

Kind regards,

Ita

Reviewer #2: Thank you for the opportunity to review your work.

1. The review protocol appears to be focused on shared decision-making on antipsychotic drug treatments in the setting of psychotic illness. However, this is not clear within the aims and/or methods of the abstract. Would the authors be able to clarify this detail in their manuscript? Thank you. We have modified the methods section of our abstract to reflect the patient population our review findings will address. The methods section in the abstract (manuscript line 13-14) now reads as follows:

Methods: This review will use realist review methodology to provide a causal understanding of how and why interventions work when implementing SDM during antipsychotic treatment choices. The cohort of interest will be those experiencing psychosis where ongoing treatment with an antipsychotic is clinically indicated.

2. The inclusion of multiple stakeholder groups including clinicians and service users as well as informal and formal caregivers is a strength of the study protocol and I commend the authors for using this comprehensive approach. When engaging with stakeholder groups that include service users and informal and formal caregivers, how will the authors ensure that perspectives of these stakeholder groups are prioritized and integrated among the larger stakeholder group of clinicians and practitioners? Thank you for raising this, it is an important point that requires due consideration. Meetings of both groups will be held separately. Clinicians will meet separately to the group representing those with lived experience of psychosis and informal and formal carers. We recognised that inviting those with clinical expertise and expertise by experience to meet together could very reasonably reduce openness amongst both groups when considering factors that hinder and facilitate shared decision making, particularly during acute psychiatric care. However, the same topics will be discussed within the respective groups. Similarities and differences in interpretation of review results, next steps in programme theory development or other tasks assigned to each stakeholder group will subsequently be discussed with the other. A peer support worker representing both lived experience of psychosis and experience of working within acute psychiatric care contexts is also a member of the clinician stakeholder group to give prominence to the voice of lived experience in clinician stakeholder group meetings.

To address your important point further within the manuscript, we have modified lines 171-174. This section now reads as follows:

To ensure independent representation of the voice of both clinical expertise and expertise by experience, meetings of the clinician and lived experience stakeholder groups will meet separately. Similarities and differences in feedback from both groups will be shared with the other, and reasons for differences explored.

3. The authors identify the patient population of interest to include adult participants aged 18-65 years. Would the authors be able to clarify the rationale for exclusion of those participants over the age of 65 years? Yes, thank you. The participant population of interest to this review are:

• Inclusion:

o Adult participants (aged 18-65) experiencing an episode of psychosis in the context of a psychotic illness where extended antipsychotic treatment is indicated.

• Exclusion:

o Participants with treatment-resistant schizophrenia due to existence of clozapine as a preferred treatment choice amongst this cohort.

o Participants experiencing substance/medication-induced psychosis or psychosis in the context of a general medical condition.

In our introduction section (lines 52-54), we outline ongoing suboptimal rates of shared decision-making amongst those with a severe mental illness in routine psychiatric care. Our rationale not to include adults aged >65 years relates to the average age at which a diagnosis of a severe mental illness is provided (usually between 20-30 years of age for schizophrenia, bipolar affective disorder, and major depressive disorder) to patients and thus, where antipsychotic treatment will be both started and continued. In such cases, the absence of shared decision-making will be most impactful. Other causes of psychotic symptoms more likely in those >65 years of age e.g., delirium, dementia, mild cognitive impairment are all situations where ongoing antipsychotic treatment is very unlikely to be clinically appropriate.

Additionally, whilst the absence of shared decision-making is applicable to those >65 years of age, ‘mechanisms’ which are responsible for the success of interventions and their interaction with contextual factors are likely to be different amongst younger versus older adults. For example, if a complex intervention offers patients additional information on antipsychotic treatment choices as one intervention strategy to improve the application of SDM, if increased confidence amongst patients aged <65 to engage in discussions is identified as the likely causal mechanism, it is reasonable to assume that this context-sensitive mechanism may not be equally applicable amongst someone who is 25 versus 75. Therefore, in line with the purpose of our review and intended recommendations for practice regarding implementation of SDM in SMI management, we will exclude studies solely addressing SMI in those >65 years of age. We hope this adequately addresses your query.

4. The authors report that during full-text screening that articles will be classified into high and low relevance based on previous established methods. It would be helpful to the reader to briefly explain how articles will be defined as having high or low relevance in the study. Thank you, this is useful feedback. We agree and have adapted lines 312-322 of our manuscript accordingly. This now reads as follows:

For those articles deemed to meet the inclusion criteria, IF will retrieve the full text and classify documents into high and low relevance, depending on their relevance to the programme theory, and based on established methods previously employed.[45] Briefly, full-text documents will be assigned a star rating of one to five, based on a global judgement of each document’s relevance and rigour. Documents assigned a one- or two-star rating will be deemed irrelevant and not included in the review. Three-star documents will be deemed irrelevant for programme theory development but potentially useful for background material. Four-star documents will be classified as relevant for programme theory refinement. Five-star documents will be deemed the most conceptually rich or contextually thick and so, most relevant to CMOC development and programme theory refinement. All 1–3-star documents will be reviewed again before finalisation of the programme theory (ies) to confirm appropriate classification.[32,43,44] A random subsample of the 10% of final documents for inclusion based on their assigned relevance and rigour judgement will be selected and assessed independently by another member of the research team (LS/EC/IM/JH/EW) to identify systematic errors.[26, 33]

5. How do the authors intend to evaluate rigor (i.e., trustworthiness) when completing qualitative data analysis during evidence synthesis? Many thanks for raising this. We believe from working with methodologists on this review there is no short answer to your question. Data are relevant in a realist review when they can help develop, corroborate, refute, or refine aspects of realist programme theory (or theories). The norm within realist reviews is that a programme theory that meets suggested quality criteria of simplicity, consilience, and analogy is underpinned by multiple arguments based on analysis and interpretation of many data sources, not all of which will represent empirical studies. We anticipate within this review the role of policy and regulation will be important for prescriber perceived willingness and ability to engage in shared decision-making – a key facilitator to making shared decision-making a reality within routine psychiatric settings. Thus, policy documents and texts addressing the impact of policy on service delivery and prescriber behaviour will be of high relevance. Whilst the option exists to use critical appraisal tools in the case of relevant qualitative and quantitative studies, no such tool will exist in the case of many documents relevant to the development of a coherent programme theory, for example, policy documents.

Thus, we will consider the quality of each individual data source, but, as outlined in the RAMESES guidelines, we will conceptualise assessments of quality at a more global level. Judgements about quality will be made at the levels of data, argument, and theory. To operationalise such assessment, we plan to do the following (as outlined in Wong, 2018 – see ref 44):

1. Find more than one source of data relevant to each aspect of the developing programme theory.

2. In cases of opinions etc; we will treat such data with scepticism initially until further supporting evidence is identified.

3. During building of programme theory, results will be presented initially partially, then in full, to stakeholder groups to aid in interpretation and to support development of a rigorous final programme theory.

4. We will seek to find to relevant substantive theory to support arguments made within the programme theory.

5. In cases of inadequate data or use primarily of data judged to be of poor quality to support any aspect of the programme theory, we will cautiously report such statements with appropriate qualifiers regarding the quality of data.

6. We will provide access to supporting data taken from each listed data source at the point of publication to allow for critical appraisal by peers.

We have also modified our manuscript now to address your important feedback. Lines 266-284 now read as follows:

As in other studies and in line with best practice within realist review methodology,[25-27, 33,34] whilst we will consider the quality of each individual data source, we will conceptualise assessments of quality at a more global level. Judgements about quality will be made at the levels of data, argument, and programme theory. To operationalise such assessments, we plan to do the following:[44]

1. Find more than one source of data relevant to each aspect of the developing programme theory.

2. In cases of opinions etc; we will treat such data with scepticism initially until further supporting evidence is identified.

3. During building of programme theory, results will be presented initially partially, then in full, to stakeholder groups to aid in interpretation and to support development of a rigorous final programme theory.

4. We will seek to find to relevant substantive theory to support arguments made within the programme theory.

5. In cases of inadequate data or use primarily of data judged to be of poor quality to support any aspect of the programme theory, we will cautiously report such statements with appropriate qualifiers regarding the quality of data.

6. We will provide access to supporting data taken from each listed data source at the point of publication to allow for critical appraisal by peers.

We have also now included the following book chapter by Wong within our reference sources (ref. 44): Data Gathering in Realist Reviews Looking for needles in haystacks | Semantic Scholar

Attachment

Submitted filename: Response to reviewers .docx

pone.0304626.s002.docx (39KB, docx)

Decision Letter 1

Eleni Petkari

15 May 2024

Shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): protocol for a realist review

PONE-D-23-34877R1

Dear Dr. Fitzgerald,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Eleni Petkari

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Eleni Petkari

17 May 2024

PONE-D-23-34877R1

PLOS ONE

Dear Dr. Fitzgerald,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Eleni Petkari

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA-P 2015 checklist.

    (DOCX)

    pone.0304626.s001.docx (34.6KB, docx)
    Attachment

    Submitted filename: Response to reviewers .docx

    pone.0304626.s002.docx (39KB, docx)

    Data Availability Statement

    No results are reported - this is a protocol paper. Data availability statement not required.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES